retatrutide efficacy weight loss and Safety of GLP‐1 Receptor Agonists, Dual Agonists, and for in Adults With Overweight or Obesity: A Bayesian NMA - Sinha - 2025 - Obesity Retatrutide—A Game Changer in Obesity

Exenatide was the worlds first clinically used GLP-1RA, developed in 1995 and approved for the treatment of type 2 diabetes mellitus (T2DM) in 2005 due to its proven ability to regulate postprandial glucose levels effectively (DeFronzo et al., 2005

Reporting Adverse Events Seek Medical Care If you experience severe side effects or adverse events (e.g., difficulty breathing, severe allergic reactions, acute hypoglycemia), discontinue use and seek immediate medical attention

Integration with Health and Fitness Apps: Our program's app offers easy integration with popular health and fitness platforms like Apple Health, Google Fit, and FitBit

Participants taking GLP-1RAs semaglutide or tirzepatide in a retrospective survey study, reported reduced drinking and binge drinking episodes 18

Complete Batch Testing Each product includes a Certificate of Analysis (COA) with verifiable data from independent laboratories